Skip NavigationSkip to Content

Targeting tubulin polymerization by novel 7-aryl-pyrroloquinolinones: Synthesis, biological activity and SARs

  1. Author:
    Bortolozzi, Roberta
    Mattiuzzo, Elena
    Dal Pra, Matteo
    Sturlese, Mattia
    Moro, Stefano
    Hamel, Ernest
    Carta, Davide
    Viola, Giampietro
    Ferlin, Maria Grazia
  2. Author Address

    Univ Padua, Lab Oncohematol, Dept Womans & Childs Hlth, I-35128 Padua, Italy.Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35731 Padua, Italy.NCI, Screening Technol Branch, Dev Therapeut Program,NIH, Div Canc Treatment & Diag,Frederick Natl Lab Canc, Frederick, MD 21702 USA.
    1. Year: 2018
    2. Date: Jan 01
  1. Journal: European Journal of Medicinal Chemistry
  2. ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER,
    1. 143
    2. Pages: 244-258
  3. Type of Article: Article
  4. ISSN: 0223-5234
  1. Abstract:

    Earlier studies had confirmed that the 7-phenylpyrroloquinolinone (7-PPyQ) nucleus was an important scaffold for new chemotherapeutic drugs targeting microtubules. For wide-ranging SARs, a series of derivatives were synthesized through a robust procedure. For comparison with the reference 3-ethyl-7-PPyQ 31, the angular geometry and substituents at the 3 and 7 positions were varied to explore interactions inside the colchicine site of tubulin. Of the new compounds synthesized, potent cytotoxicity (low and sub-nanomolar GI(50) values) was observed with 21 and 24, both more potent than 31, in both leukemic and solid tumor cell lines. Neither compound 21 nor 24 induced significant cell death in normal human lymphocytes, suggesting that the compounds may be selectively active against cancer cells. In particular, 24 was a potent inducer of apoptosis in the A549 and HeLa cell lines. With both compounds, induction of apoptosis was associated with dissipation of the mitochondrial. transmembrane potential and production of reactive oxygen species, indicating that cells treated with the compounds followed the intrinsic pathway of apoptosis. Moreover, immunoblot analysis revealed that compound 24 even at 50 nM reduced the expression of anti-apoptotic proteins such as Bcl-2 and Mcl-1. Finally, molecular docking studies of the newly synthesized compounds demonstrate that active pyrroloquinolinone derivatives strongly bind in the colchicine site of beta-tubulin. (C) 2017 Elsevier Masson SAS. All rights reserved.

    See More

External Sources

  1. DOI: 10.1016/j.ejmech.2017.11.038
  2. PMID: 29197729
  3. PMCID: PMC5798451
  4. WOS: 000428216700020

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel